MedTrace Logo

A Trial of Tisotumab Vedotin in Cervical Cancer

NCT03438396 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2023-07-25

Study results available
· View outcomes & findings →

Summary

A Single arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer.

Conditions

Interventions

DRUG

tisotumab vedotin

All patients will be treated with tisotumab vedotin once every three weeks until progression or toxicity

Sponsors & Collaborators

  • Genmab

    collaborator INDUSTRY

  • European Network of Gynaecological Oncological Trial Groups (ENGOT)

    collaborator OTHER

  • Belgian Gynaecological Oncology Group

    collaborator OTHER

  • Gynecologic Oncology Group

    collaborator NETWORK

  • Seagen Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-12
Primary Completion
2020-02-06
Completion
2022-08-02
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Czechia
  • Denmark
  • Germany
  • Italy
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03438396 on ClinicalTrials.gov